However, our study also suggested that with larger trials to standardize the correlation of CEA with the clinicopathological parameters of CRC, it is possible to measure serum CEA levels for predicting CRC disease status, e.g., tumor staging and lymph node metastasis, and also providing the guides for better clinical treatment outcome and prognosis. This evidence concerns the gene CEACAM5 and neoplasm.